Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Oct

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy

FDA Approves First-Line Pirtobrutinib for CLL-SLL

FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma

FDA Approves New Labeling of ROS1 Inhibitor for NSCLC

Charles Perou 2026 William L. McGuire Memorial Lecture Award